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ABSTRACT
Stings of hymenoptera can induce IgE-mediated hypersensitivity reactions in venom-allergic patients,
ranging from local up to severe systemic reactions and even fatal anaphylaxis. Allergic patients’ quality of
life can be mainly improved by altering their immune response to tolerate the venoms by injecting
increasing venom doses over years. This venom-speciﬁc immunotherapy is highly effective and well
tolerated. However, component-resolved information about the venoms has increased in the last years.
This knowledge is not only able to improve diagnostics as basis for an accurate therapy, but was
additionally used to create tools which enable the analysis of therapeutic venom extracts on a molecular
level. Therefore, during the last decade the detailed knowledge of the allergen composition of
hymenoptera venoms has substantially improved diagnosis and therapy of venom allergy. This review
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Hymenoptera venom hypersensitivity
There are 24 described orders of insects out of which hymenop-
tera are the main inducers of severe allergies in humans. Hyme-
noptera belonging to the genus bee (Apis), bumblebee
(Bombus), wasp (Family: Vespidae, Genus: Dolichovespula,
Polistes, Vespula), hornet (Vespa) and stinging ant (Family:
Formicidae, Genus: Myrmecia, Solenopsis), sting humans with
high frequency, and thus are the most studied in terms of
allergy and allergen-speciﬁc immunotherapy1 (Fig. 1A). Hon-
eybees (Apis mellifera) and yellow jackets (Vespula vulgaris, in
Europe also called wasp) are observed as the most frequent
inducers of allergic reactions to hymenoptera venoms in
humans, and therefore this review will mainly focus on speciﬁc
immunotherapy for allergy to stings of these species (also in
comparison to Polistes species (paper wasps), relevant in the
US and Mediterranean areas of Europe). For the review of
allergy to other insects, the reader is referred to recent publica-
tions in the ﬁeld.2,3
The frequency of stings, and thus of subsequent allergic
reactions, is dependent on geographic, environmental and eco-
logical factors.1 These factors can change very fast, which is
reﬂected by the fact that species like Polistes dominula, known
to be domestic in southern Europe, are invading the US
(1970s) from the north-east area to the west coast (1990s),4
South Africa (2008)5 and also central Europe (1956),6 which is
most probably due to climate change. Therefore, allergy to
Polistes will gain importance in these areas within the next
years.
Hymenoptera venoms are complex mixtures of various sub-
stances including numerous relevant allergens. The amount of
venom that is injected during a sting is species speciﬁc. Honey-
bees inject up to 140 mg of venom,7 with a protein content of
around 59 mg.8 In comparison, wasps inject venom with a pro-
tein content ranging from 1.7 to 3.1 mg (yellow jacket), up to
17 mg (Polistes species).7 Nevertheless, 70.6% of anaphylactic
reactions reported in europe are caused by stings of wasps and
only 23.4% and 4.1% are caused by bees and hornets,
respectively.9
Clinical manifestations of hymenoptera venom
hypersensitivity
In contrast to airborne allergens that have to cross mucosal
barriers, venom allergens are injected into the skin and
reach the blood easy and fast. Transient pain, itching and
swelling are part of the normal response to stings of hyme-
noptera due to irritative and toxic venom components. In
contrast, large local reactions (LLRs) that peak at one to
2 d after the sting and resolve 3 to 10 d later are thought
to be part of an allergic reaction to the venom. LLRs are
deﬁned by edema, erythema and pruritus and have diame-
ters greater than 10 cm.10 LLRs are supposed to be
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IgE-dependent11 or cell-mediated,10 although previous work
described them to be independent of detectable IgE (with
the detection limit at that time).12 It is believed that only
very few patients that suffer from LLRs develop more
severe reactions when they are re-stung by the same
insect, hence, they are not a predictor of the severity of
Figure 1. Relevant species and allergens in hymenoptera venom allergy. A, Taxonomy of hymenoptera,154,155 with examples of prominent species, which are relevant elic-
itors of venom allergy. B, Identiﬁed allergens of the allergy-relevant hymenoptera species Polistes dominula, Vespula vulgaris and Apis mellifera. Allergens which are
marked with an asterisk are available for routine diagnosis. Indicated in red are commercially available marker allergens, used to discriminate between allergies against
Polistes/Vespula and honeybee venom allergy. Cross-reactive allergens and their sequence identity (in percent) are shown in gray boxes.
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allergy.12-17 Due to the low risk of systemic reactions,
immunotherapy is not recommended for patients experienc-
ing only LLRs.18,19
Systemic or generalized reactions (SR) or anaphylaxis
include cutaneous urticaria, angioedema, pruritus, ﬂush,
unusual nephropathy, central and peripheral neurologic
syndromes, idiopathic thrombocytopenic purpura, rhabdo-
myolysis, vascular or respiratory symptoms, bradycardia,
arrhythmia, angina, myocardial infarction, abdominal
cramps, gastrointestinal tract and/or uterine smooth muscle
contraction.1 SRs usually begin 10 to 30 minutes after the
sting, but can also arise faster (i.e. in patients with mast cell
disorders) or slower (1–4 h) although being less life threat-
ening in the latter case. 1 It is assumed, that 0.4–0.8% of
children and 3% of adults show potentially life threating
systemic reactions after an insect sting.20,21 Anaphylactic
reactions due to stings of hymenoptera can cause a rapid
death, since cardiorespiratory arrests can be observed in a
median time of 15 min after the sting, a fact that leaves
people at risk of severe allergic reaction in great anxiety.22
The only therapeutic options for venom allergy are the pre-
scription of emergency medication (adrenaline/epinephrine
auto-injector, anti-histamines, corticosteroids) or, as the
only curative treatment, venom-speciﬁc immunotherapy
(VIT, also named allergen-speciﬁc immunotherapy).
Prevalence of venom allergy
Epidemiologic studies by Bilo et al.23 showed that most of
the venom-allergic patients suffer from LLRs (ranging from
2.4 to 26.4% in the general population) and that this num-
ber can be as high as 38% in beekeepers. Between 0.3 and
7.5% of the population studied, have experienced systemic
anaphylaxis (self-reports), whereas the number of severe
systemic reactions is as high as 14–43% among beekeepers.
The prevalence of venom-allergic reactions in children is
only 0.15–0.3%. The estimated number of annual mortalities
ranges from 0.03 to 0.45 fatalities per one million inhabi-
tants. But this number could be underestimated as many
deaths due to anaphylactic reactions to insect stings proba-
bly remain undetected.23 A survey of the European network
of severe allergic reactions (NORA) found that 48.2% (>
18 years) and 20.2% (in children) of severe anaphylactic
reactions occur due to insect stings.9
Risk factors for severe allergic reactions
Main risk factors for severe allergic reactions to insect
venoms seem to be an elevated serum tryptase concentra-
tion24 (independent of mast cell disorders) and mastocyto-
sis.25 Nevertheless, it could be shown that if tryptase
concentration is above a certain threshold, the risk of
severe insect venom-allergic reactions declines.25 The prev-
alence of severe allergic reactions was found to be 50% in
patients with a tryptase level of 20.4 to 29.9 mg/mL and
this prevalence is lower than 10% in patients with a tryp-
tase level below 6.1 mg/L and above 191 mg/L. However,
this prevalence is still higher than in the general popula-
tion.25 Further risk factors include older age, male sex,
medication of hypertension (ACE, b blockers), diagnosed
vespid allergy and preceding stings with systemic reac-
tions.26 Of note, there is no signiﬁcant difference in the
frequency of hymenoptera venom allergy in the non-atopic
and atopic population.27,28
Diagnosis and selection of patients for venom-speciﬁc
immunotherapy
The correct identiﬁcation of the allergy-relevant insect is of
major importance for accurate therapy of venom-allergic
patients, as de novo sensitizations to the wrong therapeutic
extract are possible.29 Besides the thorough and important
clinical history, several additional tools exist to analyze sensiti-
zation and/or allergy against insect venoms in vivo and in vitro.
According to the guidelines of the allergy academies of Europe
and the USA, there is a unique diagnostic algorithm for each
patient which has to be gone through in different ways,
depending on the diagnostic results.19 During diagnosis and
the decision process for venom-speciﬁc immunotherapy, clini-
cians are advised to discuss the risks and beneﬁts of therapy for
each individual case. 19
History
Standard diagnosis begins with the detailed survey of the
medical history of the patient, including previous sting reac-
tions (time course and severity of the reaction, number of
stings, all associated symptoms and treatments), the assess-
ment of potential risk factors (such as medication, cardiovas-
cular risks and other diseases) and the identiﬁcation of the
insect causing the allergic reaction.1 Unfortunately, most of
the patients have difﬁculties to correctly identify the insect
that has stung and caused the allergic reaction.30,31 Addition-
ally, the severity of stings is often under- or overestimated
because of fear, panic, exercise, heat, alcohol or underlying
cardiorespiratory disease. Furthermore, if the sting reaction
was experienced already a long time ago, sometimes it is
only poorly remembered.1 Therefore, in most of the cases
further diagnostic tests are needed to correctly identify the
allergy-relevant insect.
Skin testing
If a patient has had previous systemic reactions or severe der-
mal reactions (systemic cutaneous or LLRs) after insect stings,
further diagnostic tests are recommended. Additionally, under
special circumstances such as frequent exposure or a certain
lifestyle, further diagnosis and therapy is considerable.19,32
Despite improvements in molecular in vitro diagnosis, skin
testing is the gold standard to diagnose insect venom allergy.
There are 2 options for skin testing, skin prick testing and
intradermal testing, whereas the intradermal testing is the
more sensitive procedure. Skin testing is safe33 and should be
performed at least 2 weeks after the sting reaction to avoid pos-
sible false-negative results during the refractory period, in
which sIgE can be exausted. Ideally, skin tests should be
repeated one to 2 months later.34
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Baseline serum tryptase
It is recommended to determine the basal serum tryptase con-
centration in all patients with a history of a severe reaction after
a hymenoptera sting. Adult patients with mastocytosis and/or
elevated baseline serum tryptase are at risk to experience more
severe reactions following stings, as well as for severe side
effects during venom immunotherapy.25,26 In addition, proper
diagnosis of venom allergy in mastocytosis patients can be
affected since results of sIgE-testing might be more often nega-
tive compared with venom allergic patients without
mastocytosis.35
Speciﬁc IgE
Candidates for VIT can be considered for complementary in
vitro testing.19 This can supplement the information of the clin-
ical history and skin testing, even though testing for speciﬁc IgE
(sIgE) to the hymenoptera venoms in serum is a little loewer
than (intradermal) skin testing.34 Before the late 1970s testing
for sIgE was done with whole insect body extracts,36 but sensi-
tivity could be increased by using puriﬁed venoms. The sensi-
tivity could even be increased further by the use of natural or
recombinant single allergens.37 Limitations of in vitro testing
are demonstrated by the fact, that 15% of a population studied
by Mosbech et al.38 showed sensitization to wasp and/or bee
venom, but only 31% of those had reactions to stings. In a
smaller study group of sensitized patients (n D 94), which were
additionally diagnosed by sting challenge, only 5.3% showed
systemic reactions.39 Nevertheless, the increasing knowledge of
single allergen components in the venom of hymenoptera is
able to increase the diagnostic sensitivity and speciﬁcity in
many (unclear) cases by component-resolved diagnosis (see
below).40,41
Allergens of hymenoptera venoms
The increasing knowledge of the exact composition of hyme-
noptera venoms created added value for accurate diagnosis of
venom allergy. Moreover, it turns out that the understanding of
all allergen components, not only in the venom, but also in
therapeutic extracts used for speciﬁc immunotherapy, might
inﬂuence the outcome of the therapy.42,43
According to the WHO/IUIS Allergen Nomenclature Sub-
committee,44 protein components of one allergen source (in
this case venom) are considered as allergen if speciﬁc IgE bind-
ing from at least 2 out of 10 subjects with allergy to the source
and no IgE binding from subjects without allergy to the source
can be shown. This IgE binding should preferably be demon-
strated to the puriﬁed (natural or recombinant) protein as well
as to the extract of the source. In general, hymenoptera venoms
are composed of low molecular weight substances like biogenic
amines, basic peptides and proteins of higher molecular weight,
of which most have an enzymatic activity. One of the best char-
acterized venoms is that of the honeybee Apis mellifera, for
which detailed analyses of venom proteins are available.45
More recently 113 proteins and peptides were identiﬁed in hon-
eybee venom.46 These detailed analyses were also able to reveal
seasonal changes of venom composition.47 Together with the
proteomic data, the unraveling of the genomic information of
the honeybee48 simpliﬁed the production of single recombinant
allergens, advancing the ﬁeld of component-resolved diagnosis.
Recently, also the genome of the invasive species Polistes
dominula was sequenced,49 a fact that will probably simplify
the discovery of novel allergens of Polistes species in the future.
Unfortunately, detailed proteomic venom analyses comparable
to those for the honeybee are still missing for Vespula species.
An overview of identiﬁed honeybee, yellow jacket and Polistes
allergens is given in Table 1.
Table 1. Identiﬁed venom allergens from honeybee (Apis mellifera), yellow jacket (Vespula vulgaris) and paper wasp (Polistes dominula). MW, molecular weight; CRP, car-
bohydrate-rich protein; DPP IV, Dipeptidyl peptidase IV; DW, dry weight; MRJP, major royal jelly protein.
Allergen Name/Function MW (kDa) % of DW Potential N-glycosylation
Honeybee (Apis mellifera)
Api m 1 Phospholipase A2 17 12 1
Api m 2 Hyaluronidase 45 2 3
Api m 3 Acid phosphatase 49 1–2 2
Api m 4 Melittin 3 50 0
Api m 5 Allergen C/DPP IV 100 <1 6
Api m 6 Protease inhibitor 8 1–2 0
Api m 7 Protease 39 ? 3
Api m 8 Caarboxylesterase 70 ? 4
Api m 9 Carboxypeptidase 60 ? 4
Api m 10 CRP/icarapin 55 <1 2
Api m 11.0101 MRJP 8 65 ? 6
Api m 11.0201 MRJP 9 60 ? 3
Api m 12 Vitellogenin 200 ? 1
Vespula (Vespula vulgaris)
Ves v 1 Phospholipase A1 35 6–14 0
Ves v 2.0101 Hyaluronidase 45 1–3 4
Ves v 2.0201 Hyaluronidase (inactive) 45 ? 2
Ves v 3 DPP IV 100 ? 6
Ves v 5 Antigen 5 25 5–10 0
Ves v 6 Vitellogenin 200 ? 4
Polistes (Polistes dominula)
Pol d 1 Phospholipase A1 34 1
Pol d 4 Protease 33 6
Pol d 5 Antigen 5 23 0
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The best characterized allergen of honeybee venom is the
phospholipase A2 or Api m 1.50,44 In contrast, the venoms of
yellow jackets contain phospholipase A1 (Ves v 1, Pol d 1),
which differs in sequence and substrate speciﬁcity.50 Honeybee
and yellow jacket venoms contain hyaluronidases (Api m 2 and
Ves v 2).50 Recently, for the yellow jacket it was shown, that the
hyaluronidase exists in 2 isoforms, Ves v 2.0101 and
Ves v 2.0201, whereby the latter is an inactive, but surprisingly
the predominant isoform.51 Not described in other species so
far, are the acid phosphatase (Api m 3)52,53 and the small pep-
tide melittin (Api m 4) of honeybee venom. However, melittin
is an allergen of minor importance.54 In contrast, Api m 3 was
recently identiﬁed as a major allergen.41
Shared between almost all Vespoidea venoms (except Myr-
mecia), is an allergen named “antigen 5” (i.e., Ves v 5, Pol d 5).
Moreover, it has been shown, that there exists an antigen 5-like
protein also in honeybees, which is only expressed in the winter
and probably shows no IgE reactivity with allergic-patients’ sera
due to missing sensitizing stings in winter.47 The antigen 5 pro-
tein is of high abundance in wasp venoms, however, its func-
tion is still unknown (antigen 5 of Vespa mandarinia was
shown to be neurotoxic at the neuro-muscular junctions of lob-
ster legs).55 Since antigens 5 share a high degree of sequence
similarity, and thus of protein epitopes, they are highly cross-
reactive and recognized by many Vespoidea-allergic patients,
independent of the sensitizing species.56
Other major allergens of honeybee and yellow jacket venom
are the dipeptidyl peptidases IV (DPP IV, Api m 5 and Ves v
3), which also exhibit cross-reactivity due to sequence iden-
tity.57 Additional minor allergens include the putative protease
inhibitor Api m 6,58,59 the protease Api m 7,60 the esterase Api
m 8, the peptidase Api m 9, the major royal jelly proteins
(MRJP) 8 and 9 (Api m 11.0101, Api m 11.0201)61 and the
cross-reactive vitellogenins Api m 12 and Ves v 6.62
Another clinically relevant protein of honeybee venom is
Api m 10 (named icarapin).63 This carbohydrate-rich and
unstable allergen of unknown function with at least 9
known transcript isoforms64 was recently identiﬁed as major
allergen with important implications for diagnostics an
therapy.41,43,65 Api m 10 is not only a marker allergen for
honeybee venom allergy but also underrepresented in some
therapeutic extracts that are commonly used for honeybee
venom immunotherapy.43,65
Component-resolved diagnosis (CRD)
In the last years it has become more and more evident that test-
ing for speciﬁc IgE reactivity against several single allergens
(molecular allergology66 or component-resolved diagnosis,
CRD) is evolving as a superior tool to support classical allergy
testing. For a deep review of developments in the ﬁeld of CRD
in insect venom allergy we refer the reader to a recent review
by Ollert and Blank.42
Natural venom extracts used for diagnosis can lead to “false
positive” results due to cross-reactivity of IgE directed against
antigenic carbohydrate determinants (cross-reactive carbohy-
drate determinants, CCDs). Up to 75% of double-positive in
vitro test results with honeybee and yellow jacket venom are
caused by IgE to CCDs67 and only a minor portion by true
allergy to both venoms. IgE antibodies directed against glyco-
structures of insect and plant proteins were shown to be of
high afﬁnity68 but their clinical relevance seems to be low,
meaning that to an unknown reason they are causing no clini-
cal symptoms.69 Measuring sIgE to CCD markers (MUXF3,
horseradish peroxidase, bromelain, ascorbate oxidase) is able to
conﬁrm the presence of CCD-speciﬁc IgE antibodies as reason
of multiple positive test results. However, since speciﬁc IgE
directed against both (CCD and protein epitopes might be
present), the detection of CCD-speciﬁc IgE alone does not
allow the exclusion of sensitization to protein epitopes of multi-
ple venoms.66,67
To circumvent the problem of CCDs, allergens that cannot
be recombinantly produced in E.coli (without glycosylation)
due to complex 3-dimensional folding, can be expressed in Sf9
(Spodoptera frugiperda) insect cells without the naturally occur-
ring insect glycosylation (CCDs).70 In contrast to other hyme-
noptera venoms, venom allergens of Polistes species show no
immunologically detectable CCD-reactivity.71
Currently, commercially available hymenoptera allergens for
component-resolved allergy testing include rApi m 1, rApi m 2,
rApi m 3, rApi m 5 and rApi m 10 for honeybee venom as well
as rPol d 5, rVes v 1 and rVes v 5 for yellow jacket venom for
the ImmunoCAP platform (Phadia/Thermo Fisher Scientiﬁc)
and rApi m 1, rApi m 2 and rVes v 5 for the Immulite platform
(Siemens Healthcare Diagnostics). EUROIMMUN Medizini-
sche Labordiagnostika AG offers a different test system for
rVes v 1, rVes v 5, rApi m 1, rApi m 2, rApi m 10 and in the
near future rPol d 1 and rPol d 4. All allergens available for rou-
tine diagnosis are produced in a CCD-free form.
By using all of the commercially available allergens for
the diagnosis of honeybee venom allergy, it is possible to
detect sIgE reactivity in 94.4% of the patients.41 K€ohler
et al41 additionally calculated the contribution of sIgE to
single honeybee venom allergens to sIgE reactivity to whole
honeybee venom. It was shown, that there is high contribu-
tion of Api m 1 (19.6%) and Api m 10 (14.4%), medium
contribution of Api m 2 (7.6%), Api m 3 (7.2%) and Api m
5 (8.9%) and low contribution of Api m 4 (2%) and CCDs
(2.5%). However, until now there is no clinically meaningful
interpretation of such data. The diagnostic sensitivity for
yellow jacket (Vespula vulgaris) venom allergy was increased
to a sensitivity of almost 100% by the use of the 2 recombi-
nant marker allergens Ves v 1 and Ves v 5.35,72 Therefore,
in most cases where the venom extract-based diagnostics do
not allow the differentiation between honeybee and yellow
jacket venom allergy due to clinically irrelevant cross-reac-
tivity, the newly available component-resolved diagnostics,
using CCD-free allergens, enable the detailed characteriza-
tion of sensitization proﬁles and the identiﬁcation of the
venom causing clinical symptoms. Moreover, for patients
who are difﬁcult to diagnose due to very low levels of sIgE,
component-resolved sIgE testing shows a higher sensitivity
compared with venom extract-based testing.72-76
The situation for the diagnostic differentiation between
allergies to the different wasp species is more difﬁcult, as cross-
reactivity, independent from CCD-reactivity,35,71 is frequently
observed between Vespula and Polistes species, when sIgE to
venom extracts77 or single allergens78 is assessed. This cross-
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reactivity is not limited to Polistes and Vespula species and
shows the need for novel marker allergens.56
In the last years component-resolved approaches were also
used to analyze products used for venom immunotherapy.
These analyses revealed that particular allergens are
underrepresented in some therapeutic extracts65 and this might
be a reason for therapeutic failures.43 An overview of clinically
relevant allergens and allergens which are relevant for molecu-
lar diagnostics is given in Fig. 1B.
Basophil activation test (BAT)
In line with component-resolved diagnostics is the testing for
the activation of patient-derived basophils by allergens (baso-
phil activation test, BAT). In this test, whole blood is stimulated
with venoms (or single allergens) and the subsequent activation
of basophils is measured by the detection of CD63 upregulation
(as a consequence of cell degranulation) on the surface of baso-
phils by ﬂow cytometry.
Diagnosis with the BAT is only recommended if all other
diagnostic methods fail to detect an allergy against venom,
despite a convincing history of an allergic reaction.19,23 A study
could demonstrate that 81% out of 21 patients without detect-
able sIgE could be diagnosed using BAT.79 This method can
even be useful to gain more detailed information about the
insect, the patient is allergic to.80 Unfortunately, detailed clini-
cal information whether if BAT can predict the severity of a
reaction to an insect sting is missing due to ethical limitations
on diagnostic sting challenges.81 Moreover, there is some evi-
dence, that BAT can support the diagnosis of venom allergy in
mastocytosis patients with negative sIgE and low total IgE,82
whereas other studies are not able to show clear results for the
diagnosis of this patient group using BAT.83,84 Nevertheless, it
was demonstrated that BAT can be useful for monitoring the
effectiveness of VIT.19
Allergen-speciﬁc immunotherapy and monitoring
of venom hypersensitivity
History of VIT
The ﬁrst described case of speciﬁc immunotherapy of venom
allergy was published by Braun in 1925, reporting the desensiti-
zation of one patient sensitive to bee stings.85 This therapeutic
approach was based on the administration of a body extract of
the abdomen. Whole insect body extract-based therapy was
continued for many years, until a randomized trial proved its
ineffectiveness. In 1978, the ﬁrst randomized controlled study
using whole venom, extracted from venom sacks, was pub-
lished and demonstrated high effectiveness.86
Treatment protocols for VIT
Modern therapeutic products for speciﬁc immunotherapy of
venom allergy are venom extracts which are puriﬁed by a stan-
dardized procedure. The production process of these products
is regulated by country-speciﬁc guidelines. Moreover, due to
conﬁdential manufacturer-speciﬁc processing, the venom
extracts produced might differ in terms of composition and
allergen activity. Products for VIT are available as aqueous (or
lyophilized) extracts or as depot preparations adsorbed to alu-
minum hydroxide.
Current guidelines for VIT of the American Academy of
Allergy and Clinical Immunology (AAAAI) recommend the
treatment of patients who had a history of a systemic sting reac-
tion.19 Guidelines of the European Academy of Allergy and
Clinical Immunology (EAACI) further specify the indication
for VIT and include children and adults who had systemic reac-
tions including respiratory and cardiovascular symptoms upon
stings of hymenoptera.23 Additionally, both guidelines demand
the deﬁnite diagnosis either by skin tests and/or speciﬁc IgE
tests. Patients only suffering from LLRs should not be treated.
The injection for speciﬁc immunotherapy represents a medi-
cal task and should thus be performed by the physician and
done with a 1 ml syringe with ﬁne graduation down to 0.01 ml
with an injection needle (size 14–18, short bevel, sufﬁcient
length). The injection is made strictly subcutaneously into a
lifted skin fold a hand’s width above the olecranon on the
extensor side of the upper arms.87 The guidelines for VIT19,23
recommend a starting dose of 1 mg which is contradictory to
package inserts of therapy products (starting dose of 0.1 mg), as
it was shown, that this dose is well tolerated.88 The starting
dose is then gradually increased up to a maintenance dose of
100 mg, chosen out of historical reasons, as it was assumed that
this is the equivalent venom amount of 2 honeybee stings. To
reach the suggested maintenance dose, several protocols exist.
The conventional protocol gradually increases the amount of
injected venom during 8 to 16 weeks treatment, by injecting
increasing volumes and/or concentrations of therapy product
every week. The detailed protocol can be found on package
inserts or in the guideline for venom immunotherapy.19 Faster
protocols reach the maintenance dose within one week, 2 to 3 d
or in up to 4 to 8 hours in rush or ultrarush treatment proto-
cols, respectively.89 In clustered or modiﬁed rush up-dosing
protocols, 2 or 3 injections are given in 30 minutes intervals
every 3 to 7 d.34 All up-dosing protocols are safe in most of the
patients, with the only exception of ultrarush protocols, where
the probability of systemic reactions is somewhat increased.90
Fast up-dosing protocols are used in cases, when patients do
not have access to specialists for treatment (maintenance treat-
ment can be given by general practitioners) or when there is
need for fast protection.19,23
Several studies could show by sting challenge tests, that clin-
ical protection is reached as soon as the maintenance dose is
reached91,92 and that the treatment interval can be gradually
increased from monthly injections to a treatment course of
every 6 to 8 weeks without loss of clinical protection.93 In some
cases it was shown, that the interval can even be increased to
treatment every 3 months.19,23 After its introduction, VIT was
thought to be a lifelong treatment or a treatment that should be
performed until serum IgE and skin tests turn negative. As the
majority of patients will stay positive in diagnostic screenings,
studies could show that 80–90% of patients are protected from
having SR to sting challenge tests or ﬁeld stings when VIT is
discontinued after 3–5 y.19,23 Of note, stopping VIT after 3 y
might only be feasible for patients with good prognosis
(patients with mild reactions and a reduction of sensitivity to
venom in response to VIT, either measured by skin tests or
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sIgE serum tests) and should not be performed when sting
challenge during therapy cannot be performed.94 Extending the
treatment to 5 y protects the majority of unselected patients.95
Several speciﬁc risk factors such as older age, very severe
reactions to previous stings or during VIT (injection or sting),
treatment of less than 5 years, elevated basal serum tryptase
and/or mastocytosis, honeybee venom allergy, cardiovascular
disease, concomitant treatment with angiotensin-converting
enzyme inhibitors or b-blockers, exposure to repeated stings
and high skin sensitivity at the time point of stopping VIT are
associated with the loss of clinical protection after discontinua-
tion of VIT.96 However, all patients continue to have a 10%
chance of having a reaction to a future sting, even if venom
skin tests become negative.97 Hence, it should be kept in mind
that that longer treatment periods are associated with a lower
risk of relapse98 and that the only way to keep the risk down to
2% is to remain on maintenance immunotherapy.94 Therefore,
to keep the risk of relapse after stopping VIT as low as possible,
thought must be given to prolonging treatment or even main-
taining it lifelong, especially for high-risk patients. Considering
life-long treatment regimens it surely would be worth to inves-
tigate if treatment intervals can be extended to longer than 3
month.19,23
Immunological mechanisms of VIT
Venom-speciﬁc immunotherapy aims to induce a shift from
pro-allergic and pro-inﬂammatory Th2 conditions, present in
an allergic individual, toward a tolerating state of the immune
system (Fig. 2). The induction of this tolerogenic reaction to
venom allergens during VIT is characterized by several changes
within cellular and humoral parameters.
Whereas in an allergic individual upon a sting, venom-spe-
ciﬁc Th2 cells are thought to induce and initiate the allergic
reaction, venom-speciﬁc regulatory T cells (Treg) are thought
to be induced during VIT.99 These Tregs are able to suppress
the pro-allergic Th2 cells. Further, the Th2 suppression leads to
the reduction of the secretion of particular cytokines such as
IL-3, IL-4, IL-5, IL-9 and IL-13, reduces the activation and
degranulation of mast cells, eosinophils and basophils and,
therefore, dampens the inﬂammation.99
During the last years, the beneﬁcial role of changes within
the B cell compartment during VIT, became more and more
obvious.100 A switch from IgE-producing pro-allergic B cells
to IgG4-producing B cells with a regulatory phenotype
(secretion of IL-10 and TGF-b) was shown to be important,
as blocking IgG4 antibodies are supposed to have a protec-
tive anti-inﬂammatory role.101 These regulatory B cells are
also able to suppress venom-speciﬁc T cell proliferation102
and to induce additional Tregs,103,104 and thus amplify the
shift toward a tolerogenic phenotype of the immune system
(Fig. 2). During the course of immunotherapy, speciﬁc IgE
increases at the beginning and gradually decreases starting
some month after the initiation of immunotherapy. Never-
theless, this time course of sIgE does not correlate with the
clinical improvements of allergy.105
These protective shifts in the T and B cell compartment
together with the resulting changes in cytokine proﬁles and
antibody classes are useful characteristics which should be
monitored during VIT studies, to be able to deﬁne predictive
markers for clinical outcome of the therapy in the future.
Putative options for therapy monitoring
Until now there is no laboratory test available to predict the
safe end point of VIT. In most cases, this is examined by sting
challenge tests in a clinic situation.106 This procedure can be
quite stressful for patients because of the risk to develop severe
systemic reactions. Hence, there is ongoing research effort to
ﬁnd predictive biomarkers to monitor VIT to decide if the ther-
apy has been successful. One big drawback of most of the stud-
ies is the lack of sting challenges during or after VIT, to be able
to correlate any of the biomarkers to the success of therapy.
Figure 2. Mechanisms of venom-speciﬁc immunotherapy (VIT) compared with the
allergic immune response. Venom allergens are injected into the skin, either by
the allergy-causing insect (natural exposure) or by subcutaneous injection during
VIT. Skin-resident dendritic cells take up the allergens, process them and present
derived peptides in a complex with MHC class II molecules to allergen-speciﬁc
naive CD4C T cells. In a venom-allergic individual this leads to their differentiation
into Th2 cells (key transcription factor: GATA-3), which secrete the cytokines IL-3,
IL-5 and IL-9, contributing to the activation and degranulation of mast cells, eosi-
nophils and basophils, as well as IL-4 and IL-13 which induce the production of IgE
by B cells. These inﬂammatory processes elicit the allergic reaction and suppress a
tolerogenic phenotype of the immune response, which can be observed in individ-
uals not allergic to insect venom. A shift of this Th2-directed reaction toward a tol-
erogenic reaction is observed during VIT, characterized by the differentiation of
allergen-speciﬁc naive T cells to Tregs (key transcription factor: Foxp3) and Th1
cells (key transcription factor: T-bet). The effector cytokines of Tregs and Th1 cells
then lead to the suppression of Th2 cells and their inﬂammation-promoting func-
tions, therefore causing desensitization of mast cells and basophils, as well as the
induction of IgA-producing B cells and Bregs. These Bregs then produce protective
blocking IgG4 antibodies, further enhance the differentiation of Tregs via TGF-b
and can inhibit the differentiation of Th2 cells via IL-10 and TGF-b.99,100,102-104
Breg: regulatory B cell; Foxp3: Forkhead Box P3; GATA-3: GATA binding protein 3;
Ig: Immunoglobulin; IL: interleukin; MHC: major histocompatibility complex; T-bet:
T-Box 21; TCR: T cell receptor; TGF-b: Transforming growth factor b; Th: T helper
cell; Treg: regulatory T cell; VIT: venom-speciﬁc immunotherapy.
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Starting in 1983, studies of IgG (and IgE) antibody concen-
trations in serum against venoms were conducted, but they
could not correlate the amount of IgG to the protection against
allergy after stings.107,108 Nevertheless, monitoring the thresh-
olds of skin reactivity, total serum IgE, speciﬁc IgE, speciﬁc IgG
and speciﬁc IgG4 in patients that completed VIT showed that
no severe reactions upon ﬁeld stings were observed when VIT
induced changes in at least 3 of these parameters.109
Studying restimulated PBMCs of patients before, during and
after VIT showed a shift from Th2 to Th1 cells110 or a reduc-
tion of ICOS upregulation111 and an increase in IL-10 produc-
ing T-cells.112 None of the mentioned studies correlated
these ﬁndings to the clinical outcome of VIT. In line with these
results, an induction of regulatory T cells during VIT could be
observed. This ﬁnding also correlated with a shift of venom-
speciﬁc IgG4 and IgE, but no correlation to the clinical out-
come was made.113
B cell responses of patients on VIT showed clear similarity
to non-allergic beekeepers. This includes the expansion of IL-
10 producing BR1 cells, plasmablasts and as Api m 1-speciﬁc
class-switched memory B cells within the IgG4 producing
cells.114 However, there are no conclusive data sets that show
whether these parameters could be useful markers of clinical
successful VIT.
Studies of basophil activation before, during and after VIT
show that basophil activation sensitivity at low allergen concen-
trations decreases during VIT.115,116 Moreover, recent studies
demonstrate that there is an increase of basophil sensitivity
during therapy, but this increase declines again after 18 months
of therapy.117 The lower sensitivity of basophil activation corre-
lates with the increase of serum speciﬁc IgG4.118 Correlations
to the clinical outcome of therapy were not made in studies
with basophil activation. Nevertheless, it could be shown that a
higher sensitivity before VIT was associated with more severe
side effects during the up-dosing phase of VIT. There is evi-
dence, that no changes in basophil sensitivity can be correlated
with a positive sting challenge after therapy.116
Other changes during VIT include the increased expression
of osteopontin on mRNA119 and protein level in serum,120
changes of miRNA expression (lower expression of miRNAs
involved in allergic inﬂammation and higher expression of
those involved in tolerance induction) during VIT up-dosing121
and the decreased spontaneous release of prostaglandin E2 and
an increase of lipoxin A4 at the beginning and a decrease after
6 months of therapy.122 Non of the studied biomarkers were
linked to clinical outcomes. These studies are needed, to ﬁnd
predictive markers, so the use of potentially dangerous sting
challenge tests are not needed anymore.
Studies of effectiveness and safety
Side effects
Comparable to allergen-speciﬁc immunotherapy for other
allergens, there is a signiﬁcant risk of systemic reactions (14.2%
honeybee VIT and 2.8% wasp VIT).123 Nevertheless, a study by
Mosbech et al.124 showed that most of these systemic reactions
do not need medical treatment, proving that the side effects are
not severe. The development of LLRs at the site of injection is
experienced by 12.7%, 15.2% and 11.5% of patients undergoing
bee, wasp and bee and wasp VIT, respectively.123 Such reactions
can easily be managed by premedication with anti-histamines
or glucocorticoids.125-127 There is even evidence, that premedi-
cation with anti-histamines can improve the efﬁcacy of VIT.128
If systemic reactions occur repeatedly, especially before reach-
ing the maintenance dose, the change from standard treatment
protocols to rush up-dosing protocols, optionally together with
premedication, can be very helpful.129
Premedication may include the use of Omalizumab, a
recombinant humanized monoclonal anti-IgE antibody
approved as add-on therapy for severe allergic asthma and
chronic spontaneous urticaria. Omalizumab binds free IgE and,
hence, prevents IgE binding to FceRI on mast cells, basophils
and eosinophils, consequently leading to its downregula-
tions.130 In patients with repeated systemic reactions to VIT it
is difﬁcult to reach the maintenance dose. In several published
case reports Omalizumab has been successfully used for the
pre-treatment of patients who experienced systemic reactions
to VIT, including patients with indolent systemic mastocyto-
sis.131-135 Most of these patients were able to tolerate VIT after
Omalizumab pre-treatment. However, the duration of therapy
and optimal dosing schedule in this clinical setting is not clearly
established and a wide variety of different approaches were
used. The dosing schedule in most cases was obtained from the
approved table for asthma therapy, which is based on body
weight and total IgE. While in some cases a single injection
before initiation of VIT was used131 others used 3 to 5 injec-
tions.132,136 In other cases Omalizumab therapy and VIT were
combined for several months132,133,135 or even an unlimited
pre-treatment before every maintenance dose was adminis-
tered.134 This suggests, that the optimal treatment schedule
with Omalizumab depends on the individual response to VIT
administration.
Risk factors for severe side effects during VIT include hon-
eybee venom allergy and elevated basal serum tryptase or mas-
tocytosis.137 The use of antihypertensive medication is
controversially discussed as a risk factor, as it is a risk factor for
anaphylaxis to stings.19,26 Nevertheless, a prospective study of
patients taking antihypertensive medication during VIT could
show that there is no adverse effect on safety and efﬁcacy.138
The current guidelines recommend, that the start of VIT as
well as the up-dosing phase should be avoided during preg-
nancy, however, maintenance dose treatments should and can
be continued.19
Efﬁcacy
The ﬁrst controlled trial on the efﬁcacy of venom-speciﬁc
immunotherapy in 197886 was already able to show, that the
risk of subsequent systemic reactions caused by re-stings can be
reduced to less than 5%. The same study observed that sting
reactions that happened during VIT are usually milder than
those before treatment. In general, venom immunotherapy is
75–98% effective in preventing sting anaphylaxis,139 whereby
efﬁcacy of yellow jacket venom-speciﬁc immunotherapy is
higher compared with honeybee venom-speciﬁc immunother-
apy.140 To date it is not known why VIT is not successful in a
minor population of venom-allergic patients. So far, the only
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identiﬁed risk factor for treatment failure in honeybee venom
allergy is a predominant sensitization (> 50% of sIgE to HBV)
to the major allergen Api m 10,43 which is present in the venom
as well as in therapeutic extracts only in minimal amounts.63,65
If patients still react to the venom of hymenoptera stings in a
sting challenge setting, increasing the dose used for therapy can
protect these patients from further reactions.141 The analysis of
7 controlled clinical trials of venom immunotherapy could not
show a statistically signiﬁcant reduction of fatalities with or
without treatment due to their rarity, but a signiﬁcant reduced
risk of systemic reactions to a future sting after VIT could be
demonstrated.123 Nevertheless, the analysis of the studies men-
tioned before, suggested that venom immunotherapy is efﬁcient
concerning the prevention of allergic reactions of different
severities. Furthermore, the authors analyzed 2 non-blinded
studies in this context. Here, they could show an signiﬁcant
improvement of quality of life.123 Even after short treatment
times of one year, patients had a positive view on VIT, reduced
anxiety and less limitations to activities that cause fear of
insects.123
Novel approaches to improve immunotherapy
Allergen-speciﬁc immunotherapy in general
Allergen-speciﬁc immunotherapy is the only curative treatment
of allergies of all kinds and despite all efforts to improve
patient’s quality of life, treatment protocols have not changed
in the last years. The patient is treated with increasing dosages
of allergen up to a certain maintenance concentration and the
treatment continued for several years. The treatment is sup-
posed to re-educate the immune system toward a tolerogenic
response to the allergen source. Despite of studies showing sig-
niﬁcant reduction of symptom scores after allergen-speciﬁc
immunotherapy,142 this therapy is still facing challenges. The
probability of side effects is high and the long duration of ther-
apy (3–5 years) leads to high costs and low patient adherence.
Hence, there is a need for novel adjuvant systems to improve
the efﬁcacy of therapy and further attempts to increase the
safety of allergen-speciﬁc immunotherapy.
The most common adjuvant for allergen-speciﬁc immuno-
therapy is aluminum hydroxide (75%) which is in use since 80
y for this therapy.143,144 In products for VIT an excess of alumi-
num hydroxide is mixed with the venom extract and the mix-
ture injected subcutaneously. Unlike for prophylactic vaccines,
the manufacturers of products for allergen-speciﬁc immuno-
therapy are not required to specify the amount of aluminum in
their summary of product characteristics or package leaﬂets.144
In Europe, 1.25 mg aluminum per injection is considered as the
maximum value permitted.145 The efﬁcacy of aluminum-based
adjuvants is not subject to discussion, but it was shown that
they are able to stimulate the immune system into the
unwanted Th2 direction and to induce the production of
IgE.146,147 In allergen-speciﬁc immunotherapy the cumulative
aluminum dose can be more than 50 times higher, compared
with the vaccination against hepatitis B.144
Alternative adjuvants, which are approved for immunother-
apy, include L-tyrosine (depot effect) and the Toll-like receptor
agonist monophosphoryl lipid A (MPL). Further adjuvants like
LPS, CpG-oligodeoxynucleotides and imiquimod/resiquimod
(R837, R848) are currently investigated. Novel delivery systems
are liposomes, virus-like particles or biodegradable polymeric
carriers.148
For the reduction of side effects through IgE-mediated
adverse reactions to injected allergens and to increase the safety
of immunotherapy, allergens can be chemically modiﬁed. This
includes the use of recombinant hypoallergenic molecules,
dimers, trimers, fusion proteins or peptides. For an overview of
novel approaches in the ﬁeld of allergen-speciﬁc immunother-
apy the reader is referred to a recent review.148
Venom-speciﬁc immunotherapy
Even though novel treatment approaches were tested already in
1987149 (passive and active immunization to overcome severe
side effects), other new methods to improve venom immuno-
therapy are scarcely investigated and were only tested in animal
models. This includes treatment with T-cell epitopes, already
published in 1998,150 and the mucosal pretreatment with a sin-
gle yellow jacket allergen, a procedure that reduced sensitiza-
tion of mice to yellow jacket venom.151 Moreover, it was shown
that novel delivery systems such as PLGA microspheres and
microbubbles could be efﬁciently loaded with venom or venom
allergens.152,153 The microbubbles were even used to prevent
sensitization in a honeybee venom allergy model in mice. Issues
of study design, efﬁcacy and safety for allergen products being
developed for speciﬁc immunotherapy of allergic diseases are
addressed by guidelines of national and international medical
agencies.87,145
Conclusion
Venom-speciﬁc immunotherapy is proven to be highly effective
in improving the patient’s quality of life and to signiﬁcantly
reduce the risk for systemic sting reactions during and after
therapy. The increasing knowledge about the molecular com-
position of hymenoptera venoms has created added clinical
value over the last decade. Component-resolved diagnostics
using recombinant CCD-free allergens enables the differentia-
tion between cross-reactivity and true allergy, and thus in
many patients improves the selection of the appropriate immu-
notherapeutic intervention. Nevertheless, there is still a lack of
information about the relevant allergens present in the venoms
of different hymenoptera species. This knowledge would help
to further increase the sensitivity and speciﬁcity of diagnostics
and to improve therapeutic extracts used in the clinics. The
aim of current developments is to increase efﬁcacy of therapy,
and therefore to reduce treatment times and to increase patient
compliance. In line, there is a need to identify biomarkers that
can efﬁciently predict the end point of therapy.
As a consequence of the development of component-
resolved diagnostic approaches, enabling the identiﬁcation of
various different sensitization proﬁles to particular venom
allergens, a patient-tailored recombinant immunotherapy
would be highly desirable. Such a therapy would allow treating
the patient only with adequate amounts of the allergens he is
sensitized to. Considering the complex sensitization proﬁles of
venom allergic-patients and the unequal distribution of
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relevant allergens in therapeutic extracts, such a therapy might
have a high potential for superior efﬁcacy and, moreover,
would avoid de novo sensitizations to additional allergens.
However, due to current regulatory requirements for the
approval of novel products for allergen-speciﬁc immunother-
apy and associated costs, such developments might be in the
distant future.
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